Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study

TL;DRAbstract

In the scientific and medical community, it is recognised that exposure to certain drugs could promote the development of pulmonary arterial hypertension (PAH). These drugs, with a “class effect” (amphetamine-like) or not (dasatinib), are prescribed for serious (dasatinib, interferons) or moderate (benfluorex) pathologies and do not induce PAH in all patients [1–9]. As a result, assessment of drug history exposure from PAH patients has become essential for providing optimal disease management [10]. More studies are needed to measure nasal decongestant exposure in patients with pulmonary arterial hypertension <http://ow.ly/OFxs8> We acknowledge the French pulmonary hypertension pharmacovigilance network, VIGIAPATH, supported by the French national agency for medicines and health products safety (Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM)) as well as the French patient association HTAPFrance.

Chat with Paper

AI Agents for this Paper